ObsEva Announces Nomination o – GuruFocus.com


Geneva, Switzerland May 192022 – ObsEva SA (OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the appointment of Annette Clancy as Chair of the Board of Directors at the company’s Annual General Meeting on May 18, 2022. Ms. Clancy has been a member of the board of ObsEva Administrator since 2013 and was previously chair from November 2013 to December 2016. Ms. Clancy succeeds Dr. Frank Verwiel, who had decided to step down as chair and retire from the board. of directors, from the close of the annual general meeting. Meeting.

“We couldn’t be happier or more fortunate to have Annette returning to the role of President as we prepare for our first approvals and transition to a commercial-stage company,” said Brian O’Callaghan, CEO of ObsEva. . “Annette’s contributions to ObsEva are undisputed and her distinguished career spanning research and development, commercialization and business development provides the perfect skill set to position ObsEva for success in this next stage of growth. I also want to sincerely thank Frank for his years of contribution to the Board of Directors. The significant progress in the pipeline, which positions ObsEva for the next steps, is a testament to Frank’s leadership on the board. We wish him much success in his future endeavours. »

Ms. Clancy has over 30 years of experience in the pharmaceutical industry, including fifteen years in business development at GlaxoSmithKline (GSK) where she was most recently responsible for transactions and alliance management, responsible for innovative agreements ranging from early drug discovery partnerships to global trade agreements. alliances, mergers and acquisitions. Since retiring from GSK in 2008, Ms. Clancy has advised healthcare venture capital groups in the United States and Europe, including as an operational investor for Jeito Capital and previously a senior advisor for Frazier Healthcare Ventures. . Ms. Clancy has extensive board experience and, in addition to her role at ObsEva, she is Chairman of the private French company, Enyo SA, and a non-executive director of the Swedish public company, Sobi. Prior to joining business development, Ms. Clancy held several positions in clinical research, R&D project management and commercialization. Ms. Clancy holds a BSc (Hons) Pharmacology from the University of Bath (UK) and a series of degrees from the American Management Association (finance/marketing).

Ms. Clancy commented, “I am honored to step into the role of President of ObsEva at this pivotal time and to build on the momentum created by Frank and the leadership team as ObsEva prepares for commercial launch. . My dedication to ObsEva and belief in its prospects is longstanding, and I am excited to preside over this potentially transformational time as we pursue our first approvals and seek to shift the treatment paradigm for women with uterine fibroids and other underserved conditions.

Dr Verwiel commented: “It is a privilege to have been part of the outstanding ObsEva team over the past six years, and I am very proud of all that we have achieved together. I look forward to following ObsEva’s continued accomplishments as the company nears potential approval of linzagolix and pursues its vision of providing life-changing therapies to address the most challenging unmet needs facing the women.

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s health. Through strategic licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on novel therapies for the treatment of uterine fibroids, endometriosis and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and trades under the symbol “OBSV” and on the SIX Swiss Exchange where it trades under the symbol “OBSN”. For more information, please visit www.ObsEva.com.

Caution Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements may be identified by words such as “anticipate” , “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “might”, “ongoing”, “aim”, ” plan”, “potential”, “predict”, “should”, “will”, “would”, or the negative of these and other similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the potential approval of linzagolix by regulatory authorities, including the European Commission and the United States Food and Drug Administration (FDA), as well as the timing of such approval and the subsequent transition from ObsEva to a commercial company, the calendar or the results of interactions with regulatory authorities, the clinical development of ObsEva’s product candidates, including the timing, progress and potential therapeutic benefits of these product candidates, including linzagolix, the potential for linzagolix and other product candidates to be commercially competitive, the success of the Company’s partnerships with third parties, expectations regarding regulatory and development milestones and ObsEva’s ability to obtain and maintain regulatory approvals for its product candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in these statements. The risks and uncertainties that could cause actual results to differ materially include the uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of prior clinical trials may not be predictive of the results of subsequent clinical trials, regulatory-related interactions, including interactions with the European Medicines Agency during the marketing authorization application process and with the FDA during the new drug application process for linzagolix, ObsEva’s dependence on third parties over which it does not always have full control, and the capabilities of these third parties, the impact of the ongoing novel coronavirus outbreak and other geopolitical events, and other risks and uncertainties described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31. ber 2021 filed with the Securities and Exchange Commission (SEC) on March 10, 2022, in the report on Form 6-K filed with the e SEC on May 17, 2022 and other documents filed by ObsEva with the SEC. These documents are available on the Investors page of ObsEva’s website at www.ObsEva.com. All forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this press release, and, except as required by law, ObsEva assumes no obligation and does not intend to update any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:

CEO office contact details
Shauna Dillon
[email protected]
+41 22 552 1550

Contact Investor
Katja Buhrer
[email protected]

+1 (917) 969-3438




About Author

Comments are closed.